T-DM1 + Ribociclib: In 2016, a phase 1b study (NCT02657343) investigated the safety and sought to define the appropriate dose of T-DM1 in combination with ribociclib in advanced or metastatic HER2-positive breast cancer [70]. This evidence concerns the gene ERBB2 and breast carcinoma.